Y-mAbs Therapeutics, Inc.
YMAB
$4.73
-$0.18-3.67%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 43.52% | -19.02% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 43.52% | -19.02% | |||
| Cost of Revenue | 248.84% | -25.41% | |||
| Gross Profit | 15.05% | -18.05% | |||
| SG&A Expenses | -9.11% | -24.93% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 17.28% | -19.26% | |||
| Operating Income | 44.42% | 19.81% | |||
| Income Before Tax | -13.38% | 27.29% | |||
| Income Tax Expenses | -317.34% | 246.00% | |||
| Earnings from Continuing Operations | 2.97% | 24.34% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 2.97% | 24.34% | |||
| EBIT | 44.42% | 19.81% | |||
| EBITDA | 44.87% | 19.79% | |||
| EPS Basic | 3.51% | 25.37% | |||
| Normalized Basic EPS | 0.00% | 36.03% | |||
| EPS Diluted | 3.00% | 25.37% | |||
| Normalized Diluted EPS | 0.00% | 36.03% | |||
| Average Basic Shares Outstanding | 0.56% | 1.37% | |||
| Average Diluted Shares Outstanding | 0.56% | 1.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
